Cirrus Bio

Cirrus Bio was a diagnostic life science company specializing in developing and marketing multi-omic solutions for early disease detection and management, particularly focused on lung cancer[1][2]. In 2024, Cirrus Bio was acquired by Maverix Medical, establishing the foundation for their new diagnostics division, Maverix Dx. Previous founders and key people, David Mallery and Scott Morris, joined Maverix Dx as CEO and CSO, respectively[1]. Cirrus Bio is now inactive as an independent entity following the acquisition. The company’s main technological focus was on multi-omic diagnostic platforms to enable early cancer detection. Their pipeline included at least one marketed multi-omic diagnostic program in lung cancer[1][2]. There is no evidence of SEC registration, stock symbol, or recent independent public presence.